INTRODUCTION: Psilocybin-assisted therapy has shown significant promise in treating the cluster of mood and anxiety symptoms that comprise post-traumatic stress disorder (PTSD) but has yet to be tested specifically in this condition. Furthermore, current pharmacological and psychotherapeutic treatments for PTSD are difficult to tolerate and limited in effica...
Abstract This article reports on integration challenges that were experienced by nine individuals who attended a three-day legal psilocybin truffle retreat in the Netherlands. The study employed a qualitative phenomenological approach, using semi-structured interviews to gain an understanding of participants' ( n = 30) psilocybin experiences and their after-...
Abstract Background and Aims The hallucinogenic drug psilocybin is being widely tested in humans for the treatment of psychiatric disorders. Psilocybin and other psychedelics are proposed to work through serotonin 2a (5-HT2a) receptors, which are tightly linked to immune function. The purpose of the present study was to assess the effects of a single dose of...
Background and aimsThere is growing evidence that psilocybin, a serotonergic psychedelic substance, may be useful in the treatment of substance use disorders. However, there is a lack of data on the beliefs and attitudes towards psilocybin amongst Black individuals diagnosed with Opioid Use Disorder (OUD). This study characterized psilocybin use patterns and...
Carhart-Harris et al. performed a study in which they compared psilocybin in combination with psychotherapy to escitalopram in combination with psychotherapy for depression. In this commentary, the author first summarizes the study results: in this double blind randomized controlled trial, psilocybin yielded an antidepressant effect comparable to escitalopra...
IntroductionPsilocybin-assisted therapy may be a new treatment for major depressive disorder (MDD), with encouraging data from pilot trials. In this trial (short name: PsiDeR) we aimed to test the feasibility of a parallel-group, randomised, placebo-controlled design. The primary outcomes in this trial are measures of feasibility: recruitment rates, dropout ...
Introduction: Psilocybin mushroom use is well documented in spiritual and religious ceremonies globally. This drug is now the most popular in Europe and the USA. Objective: The objective of this study is to explore the experiences and effects of psilocybin on patients with depression and anxiety. Method: A qualitative study was conducted interviewing ten par...
Abstract This article reports on the experiences of four healthy individuals who attended a legal psilocybin truffle retreat in the Netherlands. The study employed a qualitative phenomenological approach, using semi-structured interviews to gain an understanding of participants' psilocybin experiences and their after-effects. The experiential themes that eme...
Abstract Background Psilocybin is emerging as a promising therapeutic agent for a wide range of psychiatric conditions, and clinical trials on psilocybin-assisted treatment are forthcoming in Scandinavian countries. However, little is known about attitudes towards this psychedelic compound among the general public in Nordic countries. This might represent a ...
Abstract We sought to estimate the prevalence of lifetime psilocybin use among a national sample of US adults ages 18 and older and associated demographic/substance use correlates. Pooled data from the 2015-2018 National Survey on Drug Use and Health were utilized among 168,650 individuals 18 years or older. An estimated 9.68% of individuals reported lifetim...
Abstract The recent revivification of interest in the therapeutic use of psychedelics has had a particular focus on mood disorders and addiction, although there is reason to think these drugs may be effective more widely. After outlining pertinent aspects of psilocybin and obsessive-compulsive disorder (OCD), the current review summarizes the evidence indica...
Psilocybin is a tryptamine-derived psychoactive alkaloid found mainly in the fungal genus Psilocybe, among others, and is the active ingredient in so-called "magic mushrooms". Although its notoriety originates from its psychotropic properties and popular use as a recreational drug, clinical trials have recently recognized psilocybin as a promising candidate ...
Background and aims Given the enormous global burden of depressive illness, there is an urgent need to develop novel and more effective treatments for major depressive disorder (MDD). Recent findings have suggested that psychedelic drugs may have a role in the treatment of depressive symptoms, and a number of groups are in the process of developing protocols...
Given the plethora of new studies and published papers in the scientific press and the increasingly emerging presence of articles about positive psychedelic experiences appearing in the popular media, there is little doubt that we are in the midst of a Psychedelic Renaissance. The classical psychedelic drugs LSD and psilocybin and the entactogen MDMA are sho...
Five Psilocybe species with unresolved systematic position (P. atrobrunnea, P. laetissima, P. medullosa, P. pelliculosa, and P. silvatica) were investigated using four molecular markers (EF1-α, ITS, LSU, and IGS). Phylogenetic analysis revealed that with the exception of P. laetissima, which is now rightfully classified in the genus Leratiomyces, all investi...
I. Psilocybe cubensis was cultured successfully in two media. Medium A was devised by Catalfomo and Tyler and Medium B was a modification of a medium which has been used for ergot alkaloid production by Claviceps purpurea. Only when the fungus was kept on Sabouraud agar plates.did it subsequently produce psilocybin when transferred to liquid media. A quantit...
RETURN TO ISSUEPREVNewsNEXTPSILOCYBIN STUDIES TURN A NEW LEAFScientists aim to set psychedelics research on a sound scientific footingIVAN AMATOCite this: Chem. Eng. News 2006, 84, 29, 10Publication Date (Print):July 17, 2006Publication History Published online14 November 2010Published inissue 17 July 2006https://pubs.acs.org/doi/10.1021/cen-v084n029.p010aht...
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTIsolation of Psilocybin From Psilocybe argentipes and Its Determination in Specimens of Some MushroomsYutaka Koike, Kohko Wada, Genjiro Kusano, Shigeo Nozoe, and Kazumasa YokoyamaCite this: J. Nat. Prod. 1981, 44, 3, 362-365Publication Date (Print):May 1, 1981Publication History Published online1 July 2004Published...
